Table 2.
Drug and disease characteristics of the study participants at MRRH from November 2021 to January 2022.
| Variable | Category | Frequency n (%) |
|---|---|---|
| Time since diagnosis of hypertension | 1–5 years | 153 (67.1) |
| 6–10 years | 47 (20.6) | |
| >10 years | 28 (12.3) | |
| Time since hypertension treatment | 1–5 years | 156 (68.4) |
| 6–10 years | 47 (20.6) | |
| >10 years | 25 (11.0) | |
| Presence of co-morbidity | Yes | 133 (58.3) |
| Number of co-morbidity | 1 | 94 (41.2) |
| 2 | 37 (16.2) | |
| 3 | 2 (0.9) | |
| Co-morbid conditions | Diabetes mellitus | 74 (32.5) |
| Neuropathy | 39 (17.1) | |
| HIV | 8 (3.5) | |
| Dyslipidemia | 7 (3.1) | |
| Others a | 46 (20.2) | |
| BP status | Controlled | 79 (34.6) |
| Uncontrolled | 149 (65.4) | |
| Total number of drugs | <5 | 158 (69.3) |
| ⩾5 | 70 (30.7) | |
| Drug allergy status | Yes | 13 (5.7) |
| Laboratory tests b | Yes | 98 (43) |
| Potential drug interaction | Yes | 97 (42.5) |
| Body mass index | Underweight | 9 (3.9) |
| Normal weight | 56 (24.6) | |
| Over weight | 83 (36.4) | |
| Obese | 80 (35.1) | |
| Antihypertensive drugs | Calcium channel blockers | 192 (84.2) |
| Diuretics | 126 (55.3) | |
| ARB | 119 (52.2) | |
| Beta blockers | 35 (15.4) | |
| ACEI | 12 (5.3) | |
| Others c | 6 (2.6) |
ACEI, angiotensin converting enzyme inhibitors; ARB, angiotensin receptor blockers; BP, blood pressure; HIV, human immunodeficiency virus.
a
Other co-morbidities; chronic kidney disease, arthritis, gastritis, asthma, peptic ulcer disease.
b
Availability of at least one routine laboratory test result obtained during the current encounter which include; renal function tests, urinalysis, blood glucose, thyroid stimulating hormone and lipid profile tests that are routinely ordered in hypertensive patients.
c
Other antihypertensive drugs; Alpha agonists.